Leqvio Cost in Florida 2026: Prices, Insurance, Medicaid, and Compounding

What Is Leqvio and Why Does Price Matter in Florida?

Leqvio (inclisiran) is a small interfering RNA (siRNA) therapy that inhibits PCSK9 synthesis inside liver cells, lowering LDL cholesterol by roughly 50% with only two injections per year after the initial loading series [1]. The FDA approved inclisiran in December 2021 for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C reduction beyond maximally tolerated statins [2].

Price matters because Leqvio is not a pill you pick up at a pharmacy counter. Each dose requires a clinician's office visit for subcutaneous administration. The cost of that visit stacks on top of the drug cost, and Florida Medicaid's restricted formulary leaves a large share of Florida patients without public coverage. Florida has approximately 2.9 million adults living with ASCVD according to CDC estimates, making the affordability question clinically urgent [3].

The ORION-10 trial (N=1,561, United States population) showed inclisiran 284 mg reduced LDL-C by a mean of 52.3% versus placebo at day 510 (P<0.001) [4]. ORION-11 (N=1,617, European and South African population) produced a 49.9% reduction at the same time point (P<0.001) [4]. Both trials ran 18 months, establishing the twice-yearly dosing model that defines the drug's cost structure.

Novartis List Price for Leqvio in Florida 2026

The Novartis wholesale acquisition cost (WAC) for one 284 mg/1.5 mL prefilled syringe of Leqvio is approximately $3,250 per dose as of early 2026, which annualizes to roughly $6,500 for two maintenance injections per year. Some Florida pharmacy benefit managers report an effective billed price to insurers of around $540 per month on an amortized basis, which equals roughly $6,480 annually [5].

Cash-pay patients without insurance pay close to the WAC. No major GoodRx-type coupon meaningfully discounts Leqvio because the drug is dispensed and administered in-office rather than retail, placing it outside the typical retail coupon supply chain.

The ACC/AHA 2022 Guideline on Cardiovascular Risk notes that PCSK9 inhibitors (including siRNA-based agents) are "reasonable to add" when LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy in patients with very high cardiovascular risk [6]. That clinical threshold describes millions of Florida patients, yet list pricing puts the drug out of reach for the uninsured or underinsured.

Florida Medicaid Coverage for Leqvio

Florida Medicaid does not cover Leqvio for ASCVD or HeFH as of mid-2026. The Florida Agency for Health Care Administration (AHCA) formulary restricts PCSK9 inhibitors and siRNA PCSK9 agents to very narrow carve-outs, and inclisiran is not currently listed as a covered benefit for cardiovascular indications under the standard Managed Medical Assistance (MMA) program [7].

Patients on Florida Medicaid who need LDL-C reduction beyond statins may qualify for evolocumab (Repatha) or alirocumab (Praluent) through prior authorization, but those pathways require documented statin intolerance or familial hypercholesterolemia confirmed by genetic testing or clinical criteria. Inclisiran faces an additional administrative barrier because it is classified as a medical-benefit drug (physician-administered), not a pharmacy-benefit drug, complicating Medicaid billing [8].

The practical outcome: most Florida Medicaid patients cannot access Leqvio through their state plan in 2026. Patients should ask their cardiologist to submit a prior authorization appeal citing the ACC/AHA 2022 guideline language if they believe they meet criteria, as individual MMA plans retain discretion on medical exceptions.

Commercial Insurance Coverage in Florida

Coverage varies substantially by payer. Here is a realistic breakdown of the major commercial carriers operating in Florida in 2026.

Medicare Part B. Leqvio qualifies for Medicare Part B reimbursement as a physician-administered drug under HCPCS code J3490 or a dedicated J-code. Part B covers 80% of the approved amount after the deductible; the patient pays 20% coinsurance plus any applicable supplemental gap. For a dose billing at approximately $3,250, a patient without Medigap pays roughly $650 per injection out of pocket [5].

Medicare Part D. Part D does not typically cover physician-administered drugs. Patients receiving Leqvio in a physician's office should confirm their provider is billing Part B, not Part D, to avoid a coverage gap.

Commercial plans (Florida Blue, Aetna, Cigna, UnitedHealthcare). These plans generally require prior authorization for inclisiran. Standard criteria include documented ASCVD or HeFH diagnosis, LDL-C at or above 70 mg/dL on maximally tolerated statin therapy, and trial of at least one other lipid-lowering agent (ezetimibe in most cases). Tier placement affects patient cost share; most Florida commercial formularies place inclisiran on specialty tier 4 or tier 5 [9].

Employer self-insured plans. Coverage rules vary by plan document. Some large Florida employers (particularly in the healthcare and government sectors) have adopted PCSK9 inhibitor coverage following updated ACC/AHA guidance, but inclisiran's coverage lags behind evolocumab and alirocumab in many formularies due to its newer approval date.

The ACC/AHA 2022 guideline states directly: "For patients with clinical ASCVD who are at very high risk and whose LDL-C level is 70 mg/dL or higher while receiving maximally tolerated statin therapy with ezetimibe, the addition of a PCSK9 inhibitor is recommended (Class I, Level of Evidence: A)" [6]. Citing this Class I recommendation in a prior authorization letter strengthens the case for coverage.

The Novartis Leqvio Savings Card in Florida

Novartis operates the Leqvio Co-Pay Assistance Program for commercially insured patients in the United States, including Florida. Eligible patients pay $0 out of pocket per dose, with Novartis covering the remaining cost share up to a specified annual cap [10].

Eligibility requirements as of 2026:

• Commercially insured (employer or individual market plan) in the United States
• Not covered by any federal or state government insurance program, including Medicare, Medicaid, TRICARE, or VA benefits
• Prescription written for an FDA-approved indication
• Florida residency does not affect eligibility; the program is national

Patients enroll at the Novartis patient support hub (the "Together with Leqvio" program). The prescribing physician's office typically handles enrollment paperwork. The copay card does not work for Medicare or Medicaid patients, a restriction that affects many older Florida cardiovascular patients.

A practical decision framework for Florida patients:

1. Confirm commercial insurance status and obtain a prior authorization from your cardiologist.
2. Enroll in the Novartis copay program before the first injection.
3. If Medicare Part B, verify the billing code with your cardiologist's office and estimate the 20% coinsurance before the appointment.
4. If Florida Medicaid, ask your cardiologist for a medical exception letter citing ACC/AHA Class I evidence; also ask whether you qualify for Repatha or Praluent through the Medicaid PA pathway as a bridge.
5. If uninsured, evaluate compounded inclisiran through a licensed Florida 503A pharmacy (see section below).

Compounded Inclisiran in Florida: Legality and Cost

Compounded inclisiran is legally available through 503A compounding pharmacies in Florida as of 2026, subject to strict Florida Department of Health and Florida Board of Pharmacy oversight [11]. The key regulatory distinction is between 503A pharmacies (patient-specific prescriptions, dispensed to individuals) and 503B outsourcing facilities (bulk production). Most Florida compounding pharmacies operate under 503A.

The FDA has not placed inclisiran on its "difficult to compound" list and has not issued a formal category 1 or category 2 classification under the 503A rules that would ban compounding. However, the FDA's stance on compounding biologics and complex molecules is evolving, and patients should confirm current status with a licensed Florida pharmacy [12].

Cost is the compelling argument. Several Florida 503A compounding pharmacies report pricing for compounded inclisiran near $0 per dose when dispensed through cash-pay telehealth models, though pricing varies. Even pharmacies charging a modest compounding fee produce annual costs far below the Novartis WAC. Patients considering this route should verify:

• The pharmacy holds a current Florida 503A license in good standing with the Florida Board of Pharmacy.
• The compound uses pharmaceutical-grade active pharmaceutical ingredient (API) with certificates of analysis.
• The prescribing physician orders the preparation for the patient's specific clinical need.
• The preparation is administered by a licensed clinician, not self-injected at home (inclisiran requires subcutaneous injection by a healthcare professional under FDA labeling).

A 2023 analysis published in JAMA Cardiology noted that PCSK9 inhibitor underutilization is closely tied to cost barriers, with only about 20% of eligible high-risk patients receiving guideline-directed therapy [13]. Compounded alternatives, where legally available, may address part of that gap, though the absence of FDA-reviewed manufacturing controls for compounded preparations is a real clinical consideration.

Telehealth Prescribing of Leqvio in Florida

Florida law permits telehealth prescribing of Leqvio. A physician or qualified prescriber licensed in Florida may conduct a synchronous audio-visual telehealth encounter, review lipid panel results and cardiovascular history, and write a prescription for inclisiran [14]. The physical injection itself must occur at a licensed clinical site (physician office, infusion center, or similar facility), not the patient's home.

Telehealth access matters in Florida's rural counties, where cardiologist density is low. A patient in Levy County or Hendry County may establish care with a telehealth lipidologist or cardiologist, receive the prescription, and then have the injection administered at a local primary care physician's office or outpatient clinic that stocks the drug.

Telehealth platforms operating in Florida that prescribe PCSK9-targeting therapies are subject to the Florida Telehealth Act (Section 456.47, Florida Statutes), which requires the prescriber to hold an active Florida license, conduct a real-time interactive examination, and document a patient-specific plan [14]. Platforms that prescribe without an adequate clinical evaluation violate the standard of care and may expose patients to improper prescribing.

LDL-C Reduction: What Florida Patients Can Expect Clinically

Inclisiran's mechanism differs from the monoclonal antibody PCSK9 inhibitors (evolocumab and alirocumab). Rather than binding PCSK9 protein in the bloodstream, inclisiran uses siRNA to block PCSK9 mRNA translation in hepatocytes, reducing the liver's production of PCSK9 at the source [1].

ORION-10 enrolled 1,561 patients with ASCVD in the United States. At 17 months, LDL-C fell by a mean of 52.3% in the inclisiran group versus a 0.1% decrease in the placebo group (P<0.001) [4]. The absolute LDL-C reduction from a baseline mean of 104.7 mg/dL was approximately 54.5 mg/dL.

ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents (including HeFH) outside the United States. LDL-C fell 49.9% versus placebo at day 510 (P<0.001) [4]. Adverse events were comparable to placebo except for mild injection-site reactions in about 2.6% of inclisiran patients versus 0.9% placebo.

A Cochrane systematic review of PCSK9 inhibitors published in 2023 confirmed that LDL-C reductions of 50% or greater from this drug class are associated with proportional reductions in major adverse cardiovascular events (MACE), consistent with the cholesterol hypothesis [15]. For every 1 mmol/L (38.7 mg/dL) reduction in LDL-C, major vascular events fall by approximately 22%, a relationship established across multiple statin trials and extrapolated to PCSK9 inhibition [16].

Florida-Specific Access Barriers Beyond Price

Price is not the only barrier Florida patients face. Several structural factors compound the access problem.

Administration logistics. Inclisiran must be administered by a healthcare provider. Patients who lack a cardiologist or internist willing to stock and administer the drug face a real access gap. Specialty infusion centers in Miami, Orlando, Tampa, and Jacksonville stock Leqvio, but rural Florida patients may drive 60 to 90 minutes for each injection [3].

Buy-and-bill reimbursement. Physicians who administer inclisiran buy the drug, inject it, and bill the payer for reimbursement. Cash-flow risk for small practices has slowed adoption. Large health systems and federally qualified health centers are more likely to stock the drug and handle the billing complexity.

Prior authorization burden. A 2022 AHA policy statement noted that prior authorization requirements for PCSK9 inhibitors create delays averaging 30 days and step-therapy requirements that force patients to try additional drugs (typically ezetimibe) before approval is granted, even when those patients are already on maximally tolerated statins [17]. Florida commercial plans mirror these national trends.

FH underdiagnosis. Heterozygous familial hypercholesterolemia affects approximately 1 in 250 Americans, meaning roughly 88,000 Florida adults may have HeFH, yet fewer than 10% are diagnosed according to the FH Foundation's national estimates [18]. Undiagnosed FH patients cannot access an FDA-approved indication for inclisiran until their condition is formally identified.

How Inclisiran Compares to Evolocumab and Alirocumab on Cost

Florida patients often ask whether the twice-yearly siRNA approach is cheaper than the monthly or bimonthly monoclonal antibody PCSK9 inhibitors.

Evolocumab (Repatha) lists at approximately $550 per monthly auto-injector prefilled syringe, or roughly $6,600 per year. Alirocumab (Praluent) lists at a similar range. Inclisiran at approximately $6,500 per year WAC is cost-comparable to both on an annualized basis [5].

The practical difference for Florida patients is formulary status. Evolocumab and alirocumab have been on the market since 2015 and have broader formulary coverage, including some Florida Medicaid MMA plans with prior authorization. Inclisiran's 2021 approval means its formulary penetration is lower, and prior authorization criteria are often stricter.

For self-pay patients, the monoclonal antibodies are self-injectable at home (eliminating the office visit cost), while inclisiran requires a clinical visit, adding $100 to $300 per visit in Florida depending on the practice's evaluation and management billing. Compounded inclisiran, administered in a telehealth-connected primary care office, may be the lowest total annual cost option for truly uninsured patients in Florida.

A 2021 cost-effectiveness analysis in the Journal of the American College of Cardiology estimated inclisiran's incremental cost-effectiveness ratio at approximately $450,000 per quality-adjusted life year (QALY) at list price, well above the commonly cited $150,000/QALY threshold, underscoring that meaningful price negotiation or patient assistance is necessary for inclisiran to be cost-effective at the individual patient level [19].

Practical Steps for Florida Patients in 2026

Getting Leqvio at an affordable cost in Florida in 2026 requires navigating several systems simultaneously. The steps below reflect the most direct paths based on current payer and regulatory conditions.

Step 1: Get a lipid panel and cardiovascular risk assessment. A fasting LDL-C at or above 70 mg/dL on maximally tolerated statin therapy, combined with documented ASCVD or HeFH, is the clinical threshold for guideline-supported prescribing. Request a referral to a cardiologist or lipidologist if your primary care physician is unfamiliar with inclisiran.

Step 2: Confirm your insurance benefit type. Ask your insurer whether Leqvio is covered under your medical benefit (Part B equivalent) or pharmacy benefit. This determines the copay structure and which prior authorization process applies.

Step 3: Apply for the Novartis savings program before your first dose. The copay program enrollment takes 5 to 10 business days. Your prescriber's office should submit the enrollment form with your first prescription. Patients who skip this step face the full tier 4 or tier 5 specialist cost share on the first injection.

Step 4: If Medicaid, request a prior authorization with the ACC/AHA Class I citation. Florida Medicaid MMA plans have a formal exception process. A well-written prior authorization letter citing the 2022 ACC/AHA guideline's Class I Level A recommendation, the patient's LDL-C value, ASCVD event history, and prior statin trial documentation gives the strongest possible case [6].

Step 5: If uninsured, identify a licensed Florida 503A compounding pharmacy. Confirm the pharmacy's current Florida Board of Pharmacy license status at flhealthsource.gov and ask for a certificate of analysis for the inclisiran API before agreeing to any preparation.